Chemotherapeutic and surgical strategies for germ cell tumors

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Testicular cancer has become a model for a curable neoplasm. Studies of cisplatin combination chemotherapy performed by the author's group allow the following conclusions: (1) short-duration, intensive induction therapy with the most active agents in optimal dosage is more important than maintenance therapy; (2) a modest dose escalation increases toxicity without improving therapeutic efficacy; (3) it is possible to develop curative salvage therapy for refractory germ cell tumors; and (4) preclinical models predicting synergism, such as vinblastine plus bleomycin or cisplatin plus etoposide, have clinical relevance. Testicular cancer has also become a model for new drug development. Cisplatin has been approved by the US Food and Drug Administration for testis and ovarian cancer and VP-16 and ifosfamide for refractory germ cell tumors. The success of these studies confirms the importance of the continued search for new investigational drugs in all solid tumors.

Original languageEnglish
Pages (from-to)695-706
Number of pages12
JournalChest Surgery Clinics of North America
Volume12
Issue number4
StatePublished - Nov 2002

Fingerprint

Germ Cell and Embryonal Neoplasms
Testicular Neoplasms
Cisplatin
Etoposide
Investigational Drugs
Salvage Therapy
Ifosfamide
Vinblastine
Bleomycin
United States Food and Drug Administration
Combination Drug Therapy
Ovarian Neoplasms
Neoplasms
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Chemotherapeutic and surgical strategies for germ cell tumors. / Einhorn, Lawrence.

In: Chest Surgery Clinics of North America, Vol. 12, No. 4, 11.2002, p. 695-706.

Research output: Contribution to journalArticle

@article{2216254c107c493ca3bb83e0a4241718,
title = "Chemotherapeutic and surgical strategies for germ cell tumors",
abstract = "Testicular cancer has become a model for a curable neoplasm. Studies of cisplatin combination chemotherapy performed by the author's group allow the following conclusions: (1) short-duration, intensive induction therapy with the most active agents in optimal dosage is more important than maintenance therapy; (2) a modest dose escalation increases toxicity without improving therapeutic efficacy; (3) it is possible to develop curative salvage therapy for refractory germ cell tumors; and (4) preclinical models predicting synergism, such as vinblastine plus bleomycin or cisplatin plus etoposide, have clinical relevance. Testicular cancer has also become a model for new drug development. Cisplatin has been approved by the US Food and Drug Administration for testis and ovarian cancer and VP-16 and ifosfamide for refractory germ cell tumors. The success of these studies confirms the importance of the continued search for new investigational drugs in all solid tumors.",
author = "Lawrence Einhorn",
year = "2002",
month = "11",
language = "English",
volume = "12",
pages = "695--706",
journal = "Thoracic Surgery Clinics",
issn = "1547-4127",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Chemotherapeutic and surgical strategies for germ cell tumors

AU - Einhorn, Lawrence

PY - 2002/11

Y1 - 2002/11

N2 - Testicular cancer has become a model for a curable neoplasm. Studies of cisplatin combination chemotherapy performed by the author's group allow the following conclusions: (1) short-duration, intensive induction therapy with the most active agents in optimal dosage is more important than maintenance therapy; (2) a modest dose escalation increases toxicity without improving therapeutic efficacy; (3) it is possible to develop curative salvage therapy for refractory germ cell tumors; and (4) preclinical models predicting synergism, such as vinblastine plus bleomycin or cisplatin plus etoposide, have clinical relevance. Testicular cancer has also become a model for new drug development. Cisplatin has been approved by the US Food and Drug Administration for testis and ovarian cancer and VP-16 and ifosfamide for refractory germ cell tumors. The success of these studies confirms the importance of the continued search for new investigational drugs in all solid tumors.

AB - Testicular cancer has become a model for a curable neoplasm. Studies of cisplatin combination chemotherapy performed by the author's group allow the following conclusions: (1) short-duration, intensive induction therapy with the most active agents in optimal dosage is more important than maintenance therapy; (2) a modest dose escalation increases toxicity without improving therapeutic efficacy; (3) it is possible to develop curative salvage therapy for refractory germ cell tumors; and (4) preclinical models predicting synergism, such as vinblastine plus bleomycin or cisplatin plus etoposide, have clinical relevance. Testicular cancer has also become a model for new drug development. Cisplatin has been approved by the US Food and Drug Administration for testis and ovarian cancer and VP-16 and ifosfamide for refractory germ cell tumors. The success of these studies confirms the importance of the continued search for new investigational drugs in all solid tumors.

UR - http://www.scopus.com/inward/record.url?scp=0036853913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036853913&partnerID=8YFLogxK

M3 - Article

C2 - 12471872

AN - SCOPUS:0036853913

VL - 12

SP - 695

EP - 706

JO - Thoracic Surgery Clinics

JF - Thoracic Surgery Clinics

SN - 1547-4127

IS - 4

ER -